尿激酶联合氟尿嘧啶及顺铂在晚期肿瘤所致的癌性腹水中的疗效观察

Effect of Urokinase combined with Fluorouracil and Cisplatin on malignant ascites caused by advanced tumor

目的分析晚期肿瘤所致的癌性腹水患者接受尿激酶联合顺铂、氟尿嘧啶腹腔灌注化疗的疗效。方法 10例晚期肿瘤所致的癌性腹水患者作为尿激酶组,采用尿激酶联合顺铂、氟尿嘧啶腹腔灌注化疗;文献报道的48例晚期肿瘤所致的癌性腹水患者作为热灌注组,采用腹腔热灌注化疗。比较两组患者临床疗效,观察尿激酶组患者副作用发生情况。结果热灌注组患者总有效率为66.67%(32/48),与尿激酶组的50.00%比较差异无统计学意义(P>0.05)。10例尿激酶组患者中发生肠梗阻3例,Ⅳ度骨髓抑制2例。结论尿激酶联合氟尿嘧啶、顺铂腹腔灌注化疗可用于治疗晚期肿瘤所致的癌性腹水患者,能达到与热灌注相当的疗效,有助于引流腹水,具有积极的临床意义。

Objective To analyze the efficacy of Urokinase combined with Cisplatin and Fluorouracil for intraperitoneal infusion chemotherapy in patients with malignant ascites caused by advanced tumor.Methods A total of 10 patients with malignant ascites caused by advanced tumor were regarded as Urokinase group,they received Urokinase combined with Cisplatin and Fluorouracil for intraperitoneal infusion chemotherapy.48 cases of cancerous ascites caused by advanced tumor reported in the literature were regarded as hyperthermic perfusion group,they received intraperitoneal hyperthermic perfusion chemotherapy.The clinical efficacy of the two groups was compared,and the side effects of the Urokinase group were observed.Results The total effective rate of the hyperthermic perfusion group was 66.67%(32/48),which was not significantly different from 50.00%of the urokinase group(P>0.05).In 10 cases of Urokinase group,intestinal obstruction occurred in 3 cases,andⅣdegree myelosuppression in 2 cases.Conclusion Urokinase combined with Cisplatin and Fluorouracil for intraperitoneal infusion chemotherapy can be used in patients with malignant ascites caused by advanced tumor,can achieve the same curative effect as heat perfusion,and is helpful for draining ascites and has positive clinical significance.